Hodgkin lymphoma

Journal of Clinical Investigation

Volumn 122, Issue 10, 2012, Pages 3439-3447

  Küppers, Ralf ^a   Engert, Andreas ^b   Hansmann, Martin Leo ^c  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 SC 202; AFM 13; BLEOMYCIN; BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; LENALIDOMIDE; OFATUMUMAB; PREDNISONE; PROCARBAZINE; RESMINOSTAT; STAT PROTEIN; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

CLINICAL TRIAL; GENETIC DISORDER; HODGKIN DISEASE; HUMAN; MICROENVIRONMENT; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; REVIEW;

ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; CHEMORADIOTHERAPY; CLINICAL TRIALS AS TOPIC; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NF-KAPPA B; PHENOTYPE; REED-STERNBERG CELLS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR MICROENVIRONMENT; TUMOR VIRUS INFECTIONS;

EID: 84867166303     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI61245     Document Type: Review

References (122)

1. Swerdlow SH, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Geneva, Switzerland: World Health Organization; 2008:323-325.
2. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009;9(1):15-27.
3. Schmitz R, Stanelle J, Hansmann ML, Küppers R. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol. 2009;4:151-174.
4. Greiner A, et al. Differential expression of activa-tion- induced cytidine deaminase (AID) in nodular lymphocyte-predominant and classical Hodgkin lymphoma. J Pathol. 2005;205(5):541-547. (Pubitemid 40514826)
5. Braeuninger A, Küppers R, Strickler JG, Wacker HH, Rajewsky K, Hansmann ML. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci U S A. 1997;94(17):9337-9342. (Pubitemid 27357830)
6. Marafioti T, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997;337(7):453-458. (Pubitemid 27333046)
7. Küppers R, Rajewsky K, Braeuninger A, Hansmann ML. L&H cells in lymphocyte-predominant Hodgkin's disease (Letter to the Editor). N Engl J Med. 1998;338(11):763-764. (Pubitemid 28115099)
8. Bräuninger A, Wacker HH, Rajewsky K, Küppers R, Hansmann ML. Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma. Cancer Res. 2003;63(7):1644-1651. (Pubitemid 36373657)
9. Kanzler H, Küppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184(4):1495-1505. (Pubitemid 26354704)
10. Küppers R, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A. 1994;91(23):10962-10966.
11. Marafioti T, et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000;95(4):1443-1450. (Pubitemid 30099859)
12. Müschen M, et al. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med. 2000;191(2):387-394. (Pubitemid 30060928)
13. Seitz V, Hummel M, Marafioti T, Anagnostopoulos I, Assaf C, Stein H. Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed- Sternberg cells of classic Hodgkin disease. Blood. 2000;95(10):3020-3024. (Pubitemid 30321149)
14. Ikeda J, et al. Tumorigenic potential of mononucleated small cells of Hodgkin lymphoma cell lines. Am J Pathol. 2010;177(6):3081-3088.
15. Newcom SR, Kadin ME, Phillips C. L-428 Reed-Sternberg cells and mononuclear Hodgkin's cells arise from a single cloned mononuclear cell. Int J Cell Cloning. 1988;6(6):417-431.
16. Wolf J, et al. Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood. 1996;87(8):3418-3428. (Pubitemid 26115374)
17. Küppers R, Bräuninger A, Müschen M, Distler V, Hansmann ML, Rajewsky K. Evidence that Hodgkin and Reed-Sternberg cells in Hodgkin disease do not represent cell fusions. Blood. 2001;97(3):818-821. (Pubitemid 32113421)
18. Jones RJ, et al. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood. 2009;113(23):5920-5926.
19. Küppers R. Clonogenic B cells in classic Hodgkin lymphoma. Blood. 2009;114(18):3970-3971.
20. Nakashima M, et al. The side population, as a precursor of Hodgkin and Reed-Sternberg cells and a target for nuclear factor-kappaB inhibitors in Hodgkin's lymphoma. Cancer Sci. 2010;101(11):2490-2496.
21. Shafer JA, et al. Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma. 2010;51(5):870-880.
22. Wu C, Alman BA. Side population cells in human cancers. Cancer Lett. 2008;268(1):1-9.
23. Schwering I, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed- Sternberg cells of Hodgkin lymphoma. Blood. 2003;101(4):1505-1512. (Pubitemid 36182527)
24. Stein H, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood. 2001;97(2):496-501. (Pubitemid 32060336)
25. Watanabe K, et al. Varied B-cell immunophenotypes of Hodgkin/Reed- Sternberg cells in classic Hodgkin's disease. Histopathology. 2000;36(4):353-361. (Pubitemid 30198918)
26. Torlakovic E, Tierens A, Dang HD, Delabie J. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am J Pathol. 2001;159(5):1807-1814. (Pubitemid 33062523)
27. Ammerpohl O, et al. Array-based DNA methylation analysis in classical Hodgkin lymphoma reveals new insights into the mechanisms underlying silencing of B cell-specific genes. Leukemia. 2012;26(1):185-188.
28. Ushmorov A, et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood. 2006;107(6):2493-2500. (Pubitemid 43345573)
29. Jundt F, et al. Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. Leukemia. 2008;22(8):1587-1594.
30. Mathas S, et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol. 2006;7(2):207-215. (Pubitemid 43135887)
31. Renné C, et al. Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma. Am J Pathol. 2006;169(2):655-664. (Pubitemid 44156321)
32. Küppers R, et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest. 2003;111(4):529-537. (Pubitemid 36228010)
33. Scheeren FA, et al. IL-21 is expressed in Hodgkin lymphoma and activates STAT5; evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood. 2008;111(9):4706-4715.
34. Dukers DF, et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol. 2004;164(3):873-881. (Pubitemid 38235469)
35. Raaphorst FM, et al. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol. 2000;157(3):709-715. (Pubitemid 32109362)
36. Sanchez-Beato M, et al. Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NFkappaB transcription factors. J Pathol. 2004;204(5):528-537. (Pubitemid 39585951)
37. Dutton A, et al. Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. Blood. 2007;109(6):2597-2603. (Pubitemid 46425907)
38. Hu M, et al. Multilineage gene expression precedes commitment in the hemopoietic system. Genes Dev. 1997;11(6):774-785. (Pubitemid 27157165)
39. Miyamoto T, et al. Myeloid or lymphoid promiscuity as a critical step in hematopoietic lineage commitment. Dev Cell. 2002;3(1):137-147. (Pubitemid 34778402)
40. Kapatai G, Murray P. Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma. J Clin Pathol. 2007;60(12):1342- 1349. (Pubitemid 350252944)
41. Anagnostopoulos I, Herbst H, Niedobitek G, Stein H. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1- positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood. 1989;74(2):810-816. (Pubitemid 19208827)
42. Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 1998;17(6):1700-1709. (Pubitemid 28119123)
43. Küppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol. 1998;16:471-493. (Pubitemid 28183373)
44. Bechtel D, Kurth J, Unkel C, Küppers R. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood. 2005;106(13):4345-4350. (Pubitemid 41775946)
45. Mancao C, Altmann M, Jungnickel B, Hammerschmidt W. Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus. Blood. 2005;106(13):4339-4344. (Pubitemid 41775945)
46. Bräuninger A, Schmitz R, Bechtel D, Renné C, Hansmann ML, Küppers R. Molecular biology of Hodgkin and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer. 2006;118(8):1853-1861.
47. Weber-Matthiesen K, Deerberg J, Poetsch M, Grote W, Schlegelberger B. Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin's disease. Blood. 1995;86(4):1464-1468.
48. Martin-Subero JI, et al. Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Cancer Res. 2006;66(21):10332-10338. (Pubitemid 44799752)
49. Szymanowska N, Klapper W, Gesk S, Küppers R, Martin-Subero JI, Siebert R. BCL2 and BCL3 are recurrent translocation partners of the IGH locus. Cancer Genet Cytogenet. 2008;186(2):110-114.
50. Bargou RC, et al. Constitutive nuclear factor-kap-paB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100(12):2961-2969.
51. Joos S, et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood. 2002;99(4):1381-1387. (Pubitemid 34547095)
52. Martin-Subero JI, et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood. 2002;99(4):1474-1477. (Pubitemid 34547107)
53. Otto C, et al. Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma. Br J Haematol. 2012;157(6):702-708.
54. Steidl C, et al. Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood. 2010;116(3):418-427.
55. Emmerich F, et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood. 1999;94(9):3129-3134. (Pubitemid 29512720)
56. Emmerich F, et al. Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J Pathol. 2003;201(3):413-420. (Pubitemid 37408262)
57. Jungnickel B, et al. Clonal deleterious mutations in the IkBa gene in the malignant cells in Hodgkin's disease. J Exp Med. 2000;191(2):395-401. (Pubitemid 30060929)
58. Lake A, et al. Mutations of NFKBIA, encoding IkappaBalpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases. Int J Cancer. 2009;125(6):1334-1342.
59. Kato M, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature. 2009;459(7247):712-716.
60. Schmitz R, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med. 2009;206(5):981-989.
61. Schmidt A, et al. Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma. Genes Chromosomes Cancer. 2010;49(9):803-809.
62. Martin-Subero JI, et al. Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma. Blood. 2006;108(1):401-402. (Pubitemid 43990657)
63. Joos S, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res. 2000;60(3):549-552. (Pubitemid 30094549)
64. Van Roosbroeck K, et al. JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood. 2011;117(15):4056-4064.
65. Rui L, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. 2010;18(6):590-605.
66. Weniger MA, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25(18):2679-2684.
67. Green MR, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268-3277.
68. Steidl C, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471(7338):377-381.
69. Diepstra A, et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol. 2007;25(21):3101-3108. (Pubitemid 47218058)
70. Wlodarska I, et al. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood. 2003;101(2):706-710. (Pubitemid 36077597)
71. Mottok A, Renné C, Willenbrock K, Hansmann ML, Bräuninger A. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood. 2007;110(9):3387-3390. (Pubitemid 350106334)
72. Brune V, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med. 2008;205(10):2251-2268.
73. Schumacher MA, et al. Mutations in the genes coding for the NF-kappaB regulating factors IkappaBalpha and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma. Haematologica. 2010;95(1):153-157.
74. Goldin LR, Bjorkholm M, Kristinsson SY, Turesson I, Landgren O. Highly increased familial risks for specific lymphoma subtypes. Br J Haematol. 2009;146(1):91-94.
75. Salipante SJ, et al. Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells. Proc Natl Acad Sci U S A. 2009;106(35):14920-14925.
76. Saarinen S, et al. Exome sequencing reveals germline NPAT mutation as a candidate risk factor for Hodgkin lymphoma. Blood. 2011;118(3):493-498.
77. Enciso-Mora V, et al. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat Genet. 2010;42(12):1126-1130.
78. Stanelle J, Döring C, Hansmann ML, Küppers R. Mechanisms of aberrant GATA3 expression in classical Hodgkin lymphoma and its consequences for the cytokine profile of Hodgkin and Reed/Sternberg cells. Blood. 2010;116(20):4202-4211.
79. Jundt F, Anagnostopoulos I, Förster R, Mathas S, Stein H, Dörken B. Activated Notch 1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002;99(9):3398-3403. (Pubitemid 34525322)
80. Dutton A, Reynolds GM, Dawson CW, Young LS, Murray PG. Constitutive activation of phosphati-dyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol. 2005;205(4):498-506. (Pubitemid 40361339)
81. Zheng B, et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood. 2003;102(3):1019-1027. (Pubitemid 36917799)
82. Renné C, Willenbrock K, Küppers R, Hansmann ML, Bräuninger A. Autocrine and paracrine activated receptor tyrosine kinases in classical Hodgkin lymphoma. Blood. 2005;105(10):4051-4059. (Pubitemid 40656155)
83. Lamprecht B, et al. Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med. 2010;16(5):571-579.
84. Gibcus JH, et al. Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile. Neoplasia. 2009;11(2):167-176.
85. Van Vlierberghe P, et al. Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs. Br J Haematol. 2009;147(5):686-690.
86. Navarro A, et al. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood. 2009;114(14):2945-2951.
87. Gibcus JH, et al. MiR-17/106b seed family regulates p21 in Hodgkin's lymphoma. J Pathol. 2011;225(4):609-617.
88. Costinean S, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A. 2006;103(18):7024-7029.
89. Kapp U, et al. Hodgkin's lymphoma-derived tissue serially transplanted into severe combined immunodeficient mice. Blood. 1993;82(4):1247-1256. (Pubitemid 23254000)
90. Vockerodt M, et al. Detection of clonal Hodgkin and Reed-Sternberg cells with identical somatically mutated and rearranged VH genes in different biopsies in relapsed Hodgkin's disease. Blood. 1998;92(8):2899-2907. (Pubitemid 28469105)
91. Carbone A, Gloghini A, Gruss HJ, Pinto A. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol. 1995;147(4):912-922.
92. Nozawa Y, Wakasa H, Abe M. Costimulatory molecules (CD80 and CD86) on Reed-Sternberg cells are associated with the proliferation of background T cells in Hodgkin's disease. Pathol Int. 1998;48(1):10-14.
93. Marshall NA, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103(5):1755-1762. (Pubitemid 38268969)
94. Yamamoto R, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008;111(6):3220-3224.
95. Juszczynski P, et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A. 2007;104(32):13134-13139. (Pubitemid 351737605)
96. Gandhi MK, et al. Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood. 2007;110(4):1326-1329. (Pubitemid 47281432)
97. Newcom SR, Gu L. Transforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease. J Clin Pathol. 1995;48(2):160-163.
98. Engert A, Horning SJ. Hodgkin Lymphoma. Heidelberg, Germany: Springer; 2011.
99. Engert A, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640-652.
100. Eich HT, et al. Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol. 2008;184(8):406-410.
101. Fermé C, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007;357(19):1916-1927. (Pubitemid 350074687)
102. Engert A, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extend-ed-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007;25(23):3495-3502. (Pubitemid 47310889)
103. Raemaekers J, et al. The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2002;38:S107-S113.
104. Federico M, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol. 2009;27(5):805-811.
105. Viviani S, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203-212.
106. Engert A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791-1799.
107. Nogova L, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte- predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol. 2005;16(10):1683-1687. (Pubitemid 41510144)
108. Ekstrand BC, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003;101(11):4285-4289. (Pubitemid 36857790)
109. Schulz H, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111(1):109-111.
110. Franklin J, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol. 2006;17(12):1749-1760. (Pubitemid 44884048)
111. Gallamini A, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746-3752. (Pubitemid 47372616)
112. Spaepen K, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol. 2001;115(2):272-278. (Pubitemid 34203488)
113. Borchmann P, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood. 2003;102(10):3737-3742. (Pubitemid 37409395)
114. Younes A, et al. Results of a pivotal phase II study of Brentuximab Vedotin (SGN-35) for patients with relapsed or refractory Hodgkin lymphoma. J Clin Oncol. 2011;29(suppl; abstr 8031).
115. Younes A, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-1821.
116. Affimed Therapeutics AG. A Study to Assess AFM13 in Patients With Hodgkin Lymphoma. NIH Web site. http://clinicaltrials.gov/ct2/show/ NCT01221571. Updated June 26, 2011. Accessed April 10, 2012.
117. Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea. Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma. NIH Web site. http://clinicaltrials.gov/ct2/show/ NCT01195766. Updated September 3, 2010. Accessed April 10, 2012.
118. Böll B, et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol. 2009;148(3):480-482.
119. 4SC AG. Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma (SAPHIRE). NIH Web site. http://clinicaltrials.gov/ct2/show/ NCT01037478. Updated February 29, 2012. Accessed April 10, 2012.
120. 4SC AG. Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS). NIH Web site. http://clinicaltrials. gov/ct2/show/NCT01344707. Updated February 16, 2012. Accessed April 10, 2012.
121. Johnston PB, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85(5):320-324.
122. Tiacci E, et al. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma [published online ahead of print]. Blood. doi:10.1182/blood-2012-05-428896.